Proteomic analysis of gemcitabine-resistant (GemR) versus paired control human pancreatic cancer cells (PCCs)

In search of potential markers of treatment response, comparative LC-MS/MS-based proteomic analysis of GemR and paired control PCCs was performed. It includes four different PCC lines including three primary - PCC-1 (c1), PCC-2 (c2), PCC-7 (c3) and Mia PaCa-2 (c4). Cells were maintained in DMEM supplemented with 10% FBS, with or without gemcitabine (50-150 nM) for upto 40 passages. Cell lysates in triplicate from GemR and paired control cells collected at six different passages (p10, p20, p25, p30, p35, and p40) during treatment period were analyzed using LC-MS/MS